Roche collaborated with Eli Lilly and Company to support the development of Roche’s Elecsys® Amyloid Plasma Panel

Roche collaborated with Eli Lilly and Company

Roche (6: RO, ROG; OTCQX: RHHBY) announced that it has entered into a collaboration with Eli Lilly and Company to support the development of Roche’s Elecsys® Amyloid Plasma Panel (EAPP).

Up to 75% of people live with Alzheimer’s symptoms but do not have a diagnosis due to impediments to early and accurate detection of the disease. On average, 2.8 years passed before a diagnosis was made in those who obtained one1. Making a person’s journey to diagnosis quicker and more accessible will be crucial to addressing the enormous burden that Alzheimer’s is placing on healthcare systems. In the end, this will make it possible to get access to the right new treatments when they become available.

The joint goal of Roche and Lilly to support patients by enhancing the path to an early and accurate diagnosis and treatment is in line with this collaboration. If approved, the EAPP test would be an additional tool to help symptomatic patients detect low chance of amyloid pathology and decide whether to move through with additional screening and testing that could help confirm a diagnosis.

According to Matt Sause, CEO of Roche Diagnostics, “We are thrilled to be cooperating with Lilly on such a significant area of unmet medical need.” By the year 2050, there will be approximately 140 million people living with dementia, up from the current number of over 55 million. To guarantee that these individuals receive a prompt and accurate diagnosis, cooperation is crucial. The Elecsys® Amyloid Plasma Panel may expedite a person’s path to diagnosis and, consequently, access to therapeutic treatments.

Lilly group vice president for Neuroscience R&D and president of Avid Radiopharmaceuticals Mark Mintun commented, “We are thrilled to be partnering Roche to help the development of yet another potential diagnostic tool.” “We look forward to the rich data and continuing field collaboration that will be essential to expedite the ecosystem to aid in a quick and accurate diagnosis of Alzheimer’s,” the statement reads.

The U.S. Food and Drug Administration designated the EAPP as a breakthrough device, Roche reported in July. With its Elecsys® beta-Amyloid (1-42) CSF II (Abeta42) and Elecsys® Phospho-Tau (181P) CSF (pTau181) assays, which detect Alzheimer’s pathology in its early symptomatic stage, Roche also got FDA 510(k) clearance in December 2022.

More About the Elecsys® Amyloid Plasma Panel

The Elecsys Amyloid Plasma Panel measures phosphorylated Tau (pTau) 181 protein assay and apolipoprotein (APOE) E4 assay in human blood plasma. Elevations in pTau181 occur in early stages of Alzheimer’s, while the presence of APOE4 constitutes the most common genetic risk factor for Alzheimer’s disease. The result is intended for consideration in conjunction with other clinical information to advise for further confirmatory testing with amyloid positron emission tomography (PET) or cerebrospinal fluid (CSF) testing. Patients testing negative with the Elecsys Amyloid Plasma Panel are unlikely to be amyloid positive and should be investigated for other causes of cognitive decline.

More About Roche in Alzheimer’s disease

With more than two decades of scientific research in Alzheimer’s, Roche is working towards a day when we can detect the disease early and stop its progression to preserve what makes people who they are. Today, the company’s Alzheimer’s portfolio spans investigational medicines for different targets, types and stages of the disease. It also includes approved and investigational tools, including digital and blood-based tests and cerebrospinal fluid (CSF) assays, aiming to more effectively detect, diagnose, and monitor the disease.

Yet the global challenges of Alzheimer’s go well beyond the capabilities of science, and making a meaningful impact requires collaboration both within the Alzheimer’s community and outside of healthcare. We will continue to work together with numerous partners with the hope we can transform millions of lives.

More About Roche

Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world’s largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving the lives of people around the world. We are a pioneer in personalised healthcare and want to further transform how healthcare is delivered to have an even greater impact.

To provide the best care for each person we partner with many stakeholders and combine our strengths in Diagnostics and Pharma with data insights from the clinical practice.

In recognising our endeavor to pursue a long-term perspective in all we do, Roche has been named one of the most sustainable companies in the pharmaceuticals industry by the Dow Jones Sustainability Indices for the thirteenth consecutive year. This distinction also reflects our efforts to improve access to healthcare together with local partners in every country we work. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.

About Publisher

IR Research Publication is Publisher, Editorial, and Profile Building Service Provider. It Covers the Publication of Multiple Reputed Journals in the field of Biological, Medical, Pharmaceutical, and Life Sciences. IR Research Publication provides news on CDSCO decisions and FDA decisions, pharmaceutical industries, generic drugs, patents, and other pharma news.
For more details Click here

For more Pharma related updates Click here

 

 

Leave a Reply

Your email address will not be published. Required fields are marked *

error

Enjoy this blog? Please spread the word :)

WhatsApp
LinkedIn
Share
Follow by Email
RSS